A GHRH(1-29) analogue formerly approved for pediatric diagnostic and treatment contexts and later discontinued commercially. This record separates established identity and source-linked research context from protocol or commercial fields that are not yet supportable.
FEMETRIC RECORD · PUBLICSermorelin
NeuroendocrineBody CompositionRecovery
Status
Discontinued
Related
3
Sources
1
UPDATED 2026-09-13
01
Protocol references
SOURCE-LINKED
LITERATURE-DERIVED REFERENCE
Source-linked research context
No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.
Route
Subcutaneous
Frequency
See indexed source
Duration
Not indexed
Escalation
Not established
Stage detail pending source extractionStarting and target doses are indexed. Intermediate steps are intentionally not inferred.
LITERATURE-DERIVED REFERENCEClinical Interventions in Aging, 2006Verified 2026-09-13
Sermorelin stimulates pituitary GH release through the GHRH receptor. Historical approval and discontinuation do not validate modern anti-aging or performance claims.
Mechanism summaries are stored with field-level source provenance for editorial audit.
07
Related research goals
08
Related peptides
01PEPTIDE
Tesamorelin
A GHRF analogue approved for reduction of excess abdominal fat in adults with HIV and lipodystrophy, with additional research contexts.
Body CompositionFat LossNeuroendocrine
02PEPTIDE
CJC-1295
A long-acting growth hormone-releasing hormone analogue studied in healthy adults for GH and IGF-1 pharmacodynamics.
NeuroendocrineBody CompositionRecovery
03PEPTIDE
Ipamorelin
A selective ghrelin-receptor agonist studied as a growth hormone secretagogue, with limited modern human clinical evidence.